Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Raboud, Janet M ^a,b   Loutfy, Mona R ^a,c,d,e   Su, DeSheng ^b   Bayoumi, Ahmed M ^a,c,f,g   Klein, Marina B ^h   Cooper, Curtis ⁱ   Machouf, Nima ^j   Rourke, Sean ^a,c,f,k   Walmsley, Sharon ^b,c   Rachlis, Anita ^c,l   Harrigan, P Richard ^m,n   Smieja, Marek ^o   Tsoukas, Christos ^h   Montaner, Julio S G ^m,n   Hogg, Robert S ^n,p  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e MAPLE LEAF MEDICAL CLINIC   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j Clinique Medicale l'Actuel   (Canada)

^k ONTARIO HIV TREATMENT NETWORK   (Canada)

^l SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^o MCMASTER UNIVERSITY   (Canada)

^p SIMON FRASER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGING; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DEVELOPED COUNTRY; DISEASE SURVEILLANCE; DRUG RESPONSE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH INSURANCE; HEALTH SURVEY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RATE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT CARE; REGIONALIZATION; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VIRUS LOAD; AGE; DRUG MONITORING; GEOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; SUBSTANCE ABUSE; UTILIZATION REVIEW; VIROLOGY;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; CANADA; DRUG MONITORING; FEMALE; GEOGRAPHY; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 77951236721     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-40     Document Type: Article

References (13)

1. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fisch MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA, . International AIDS Society - USA Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-70. 10.1001/jama.300.5.555, 18677028, International AIDS Society - USA.
2. Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J, Were W, Mermin J. CD4+ T-cell monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 49:477-84. 10.1097/QAI.0b013e318186eb18, 18989232.
3. Hirsch MS, Gunthard HF, Schapiro M, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society- USA panel. Clin Infect Dis 2008, 47:266-85. 10.1086/589297, 18549313.
4. Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, Ford N, Kyawkyaw M, Talangsri P, Taochalee N. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg 2009, 103:601-6. 10.1016/j.trstmh.2008.11.007, 19110288.
5. Raboud JM, Abdurrahman ZB, Major C, Millson P, Robinson G, Rachlis A, Bayoumi AM. Nonfinancial factors associated with decreased plasma viral load testing in Ontario, Canada. J Acquir Immune Defic Syndr 2005, 39:327-32. 10.1097/01.qai.0000143603.94728.b2, 15980694.
6. Laine C, Zhang D, Hauck WW, Turner BJ. HIV-1 RNA viral load monitoring in HIV-infected drug users on antiretroviral therapy; relationship with outpatient care patterns. J Acquir Immune Defic Syndr 2002, 29:270-4.
7. Druyts EF, Yip B, Lima VD, Burke TA, Lesovski D, Fernandes KA, McInnes CW, Rustad CA, Montaner JSG, Hogg RS. Health care services utilization stratified by virological and immunological markers of HIV: evidence from a universal health care setting. HIV Medicine 2009, 10:88-93. 10.1111/j.1468-1293.2008.00656.x, 19200171.
8. Palmer AK, Klein MB, Raboud JM, Cooper C, Loutfy M, Machouf N, Montaner JSG, Rourke SB, Smieja M, Tsoukas C, Yip B, Milan D, Hogg RS, . the CANOC Collaboration Cohort Profile: The Canadian Observational Cohort (CANOC) Collaboration. International Journal of Epidemiology the CANOC Collaboration.
9. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-30. 10.2307/2531248, 3719049.
10. Lima V, Harrigan R, Montaner JSG. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009, 51:3-6. 10.1097/QAI.0b013e31819e721b, 19247185.
11. Smit E, Bhattacharya S, Osman H, Taylor S. Increased Frequency of HIV-1 Viral Load Blip Rate Observed After Switching from Roche Cobas Amplicor to Coas Taqman Assay. J Acquir Immune Deficiency Syndr 2009, 51:364-5.
12. Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD, . the EuroSIDA study group Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?. AIDS 2008, 22:2381-2390. 10.1097/QAD.0b013e328317a6eb, 18981778, the EuroSIDA study group.
13. Boulos D, Yan P, Schanzer D, Remis RS, Archibald CP. Estimates of HIV prevalence and incidence in Canada, 2005. Canada Communicable Disease Report 2006, 32:164-74.